Wanbang Medicine (301520.SZ) will distribute 5 yuan for every 10 shares in 2023. The equity registration day is June 20th.

Wanbang Pharmaceutical (301520.SZ) announced that the company will implement the annual equity distribution for 2023, with 10 shares per...

Zhitong FinanceJun 14 08:47 ET

Wanbang Pharmaceutical (301520.SZ): has developed a sample analysis method for Semaglutide.

On June 5th, Gelon Hui reported that Wanbang Pharma (301520.SZ) has developed a sample analysis method for Simcereglutide, which is one of the clinical research links. At present, there are no related orders.

Gelonghui FinanceJun 5 03:03 ET

Wanbang Pharmaceutical (301520.SZ): The company has not yet carried out drug research and development work for the KP.2 variant

Gelonghui, May 20 | Wanbang Pharmaceutical (301520.SZ) said on the investor interactive platform that the company has not yet carried out drug research and development work on the KP.2 variant.

Gelonghui FinanceMay 20 03:41 ET

Anhui Wanbang Pharmaceutical Technology's (SZSE:301520) Earnings Might Be Weaker Than You Think

Shareholders didn't seem to be thrilled with Anhui Wanbang Pharmaceutical Technology Co., Ltd.'s (SZSE:301520) recent earnings report, despite healthy profit numbers. Our analysis has found some conc

Simply Wall StApr 26 18:09 ET

Wanbang Pharmaceutical (301520.SZ): 2023 net profit of 108 million yuan, plans to distribute 5 yuan

Gelonghui, April 19 | Wanbang Pharmaceutical (301520.SZ) announced its 2023 annual report, with operating income of 342 million yuan, up 31.07% year on year; net profit attributable to shareholders of listed companies was 108 million yuan, up 9.48% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 97.6952 million yuan, up 12.89% year on year; basic income per share was 2.00 yuan; it plans to distribute 5 yuan (tax included) to all shareholders for every 10 shares.

Gelonghui FinanceApr 19 07:10 ET

China Merchants Securities: Demand for outsourcing generic drug development services increases, and the performance of listed companies related to generic CRO maintains a relatively rapid growth rate

From a long-term development perspective, imitation CRO related companies are expected to fully benefit from advanced market demand, business model innovation, and customer base expansion, and achieve continuous growth in performance. First-tier enterprises are expected to increase their market share in industrial upgrading competition.

Zhitong FinanceApr 16 02:02 ET